Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Breast 1

Conditions

Bilateral Breast Carcinoma 1

Interventions

Specimen Handling 49Letrozole 42Fulvestrant 42Paclitaxel 38pembrolizumab 34Magnetic Resonance Spectroscopy 31Carboplatin 31ribociclib 26Trastuzumab 26Biopsy 26exemestane 23Anastrozole 23Capecitabine 22palbociclib 21pertuzumab 20Tamoxifen 19trastuzumab deruxtecan 18abemaciclib 18Cyclophosphamide 17Taxes 15Radiotherapy 14130-nm albumin-bound paclitaxel 12elacestrant 11Docetaxel 11sacituzumab govitecan 9olaparib 9Standard of Care 9Radiation 9Goserelin 9Gemcitabine 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Epothilones × Breast × 30 days × Clear all
NCT00877500 2026-05-22

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
116 enrolled
Breast

Bilateral Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡